



RESEARCH

Open Access

Direct interaction between GluR2 and GAPDH regulates AMPAR-mediated excitotoxicity

Min Wang¹, Shupeng Li¹, Hongyu Zhang¹, Lin Pei¹, Shengwei Zou¹, Frank J S Lee¹, Yu Tian Wang² and Fang Liu^{1,3,4*}

Abstract

Over-activation of AMPARs (α -amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptors) is implicated in excitotoxic neuronal death associated with acute brain insults, such as ischemic stroke. However, the specific molecular mechanism by which AMPARs, especially the calcium-impermeable AMPARs, induce neuronal death remains poorly understood. Here we report the identification of a previously unrecognized molecular pathway involving a direct protein-protein interaction that underlies GluR2-containing AMPAR-mediated excitotoxicity. Agonist stimulation of AMPARs promotes GluR2/GAPDH (glyceraldehyde-3-phosphate dehydrogenase) complex formation and subsequent internalization. Disruption of GluR2/GAPDH interaction by administration of an interfering peptide prevents AMPAR-mediated excitotoxicity and protects against damage induced by oxygen-glucose deprivation (OGD), an *in vitro* model of brain ischemia.

Introduction

Glutamate is the principal excitatory neurotransmitter in the brain and is involved in numerous physiological functions including neuronal circuit development, learning and memory [1]. Glutamate-induced neurotoxicity is implicated in neuropathological disorders such as stroke and epilepsy [2]. The effects of glutamate are mediated via two major subfamilies of ligand-gated ion channels: NMDAR (N-methyl-D-aspartate receptor) and AMPAR [3]. AMPAR mediates fast synaptic transmission at excitatory synapses, while NMDAR is critical in producing a number of different forms of synaptic plasticity [1]. In neurons, mature AMPA receptors are found as tetramers consisting of various combinations of GluR1 to GluR4 subunits [4], each of which has the same topology: three transmembrane domains and one membrane re-entrant loop. All subunits are permeable to both Na⁺ and Ca²⁺ ions with the exception of GluR2, which is uniquely impermeable to Ca²⁺. The majority of AMPA receptors *in vivo* contain GluR2 subunits whose ion selectivity is dominant over other subunits [5].

The accumulation of glutamate, which occurs immediately after ischemia, results in excessive stimulation of glutamate receptors and leads to neurotoxicity [6,7]. NMDAR-mediated neurotoxicity is dependent upon extracellular Ca²⁺ and is likely mediated by Ca²⁺ influx directly through receptor-gated ion channels [6,7]. AMPAR is also tightly associated with a selective pattern of neuronal loss in certain brain areas following both global and focal ischemia [8-20]. Similar to what is reported for NMDAR, excitotoxicity mediated by AMPAR lacking the GluR2 subunit is thought to be dependent on ion influx (Ca²⁺, Zn²⁺) through AMPAR channels following agonist stimulation [19-21]. However, as most native AMPARs in the hippocampus contain the GluR2 subunit and therefore are likely impermeable to Ca²⁺ [22-26], it is still unclear how activation of the GluR2-containing AMPAR leads to neuronal cell death.

Protein-protein interactions with the AMPAR have been reported to affect function of AMPAR, among which the best characterized ones, such as GRIP (glutamate receptor interacting protein), ABP (AMPA-binding protein), SAP97 (synapse-associated protein-97), PICK1 (protein interacting with C kinase-1), stargazin, NSF (N-ethylmaleimide-sensitive factor) and AP2 (adaptor protein-2) [27-34], bind to the intracellular carboxyl terminus of AMPAR. They regulate AMPAR function in a variety of ways, including modulation of AMPAR

* Correspondence: f.liu.a@utoronto.ca

¹Department of Neuroscience, Centre for Addiction and Mental Health, Toronto, Canada

³Brain Research Center, University of British Columbia, Vancouver, Canada
Full list of author information is available at the end of the article

subcellular localization, clustering and/or trafficking. Recent studies have demonstrated that NARP (neuronal activity-regulated pentraxin) and N-cadherin interact with the amino terminus (NT) of AMPAR subunits and play an important role in AMPAR clustering [35] as well as dendritic spine formation [36]. In the present study, we have identified a new AMPAR-interacting partner, GAPDH. We show that secreted GAPDH binds specifically to the extracellular NT domain of the GluR2 subunit, a process which is promoted by AMPAR activation. Disruption of GluR2/GAPDH interaction prevents AMPAR-mediated excitotoxicity and protects against damage in OGD model.

Results

GluR2 subunit directly interacts with GAPDH via its Y142-K172 region of N-terminus

To identify potential proteins that may interact with the NT domain of AMPAR subunits, we used GST-fusion proteins GST-GluR1_{NT} (A₁₉-E₅₃₈) and GST-GluR2_{NT} (V₂₂-E₅₄₅) to affinity “pull-down” proteins from solubilized rat hippocampal tissues along with GST alone as a control. The precipitated proteins were then identified by Coomassie brilliant blue staining following SDS-PAGE. A prominent protein band of ~37 kD was specifically precipitated by GST-GluR2_{NT}, but not by GST alone or GST-GluR1_{NT} (Figure 1A). Mass spectrometry analysis (LC-MS/MS, Protana [now Transition Therapeutics]) of this protein band identified three fragments that were homologous to and covered 17% of the sequences within rat GAPDH (VIISAPSADAPMFVMGVNHEK; VIHDNFGIVEGLMTTVHAIATQK; VPTPNVSVVDLTCR). These results suggested that the GluR2 subunit might form a protein complex with GAPDH through its NT domain. We then confirmed the GluR2/GAPDH interaction with affinity purification experiments using GST-GluR2_{NT}, GST-GluR2_{CT} (I₈₃₃-I₈₈₃) and GST alone. Subsequent Western blot analysis using a GAPDH antibody confirmed the association between GAPDH and GluR2_{NT}, but not GluR2_{CT} (Figure 1B).


Before conducting further experiments, we examined whether GluR2/GAPDH complex exists *in vivo*. As shown in Figure 1C, the GluR2 antibody was able to co-immunoprecipitate (Co-IP) GAPDH from solubilized proteins extracted from rat hippocampal tissues confirming the *in vivo* association between GluR2 and GAPDH. In order to smooth the way for the following functional studies, three GluR2_{NT} GST-fusion proteins (GluR2_{NT1}: V₂₂-S₂₇₁, GluR2_{NT2}: K₂₇₂-I₄₂₁, GluR2_{NT3}: L₄₂₂-E₅₄₅) were constructed (Figure 1D) and utilized in affinity purification experiments to delineate the region (s) of GluR2_{NT} involved in the interaction with GAPDH. As shown in Figure 1E, GST-GluR2_{NT1}, but not GST-GluR2_{NT2}, GST-GluR2_{NT3} or GST alone, precipitated GAPDH

indicating that the GluR2 subunit interacts with GAPDH through its NT region V₂₂-S₂₇₁. A series of truncations of the GluR2_{NT1} region were then created to map the site that interacts with GAPDH (Figure 1D). As shown in Figure 1F and 1G, GST-GluR2_{NT1-3} (H₁₂₂-K₁₇₂) and GST-GluR2_{NT1-3-2} (Y₁₄₂-K₁₇₂) were able to precipitate GAPDH from rat hippocampal tissues.

While these results suggested the existence of the GluR2/GAPDH complex, it did not clarify whether this GluR2/GAPDH complex was formed through either a direct interaction or was mediated indirectly by other accessory binding proteins. Therefore we performed *in vitro* binding assays to examine whether GAPDH and the GluR2 subunit directly interact with each other. As shown in Figure 1H, *in vitro* translated [³⁵S]-GAPDH probe bound with GST-GluR2_{NT1} but not with GST-GluR2_{NT2}, GST-GluR2_{NT3} or GST alone, indicating the specificity of the direct protein-protein interaction between GAPDH and GluR2_{NT1}. Consistent with the results from affinity purification experiments, the *in vitro* translated [³⁵S]-GAPDH probe only hybridized with GST-GluR2_{NT1-3} and GST-GluR2_{NT1-3-2} (Figure 1I, J). Together, these data provided *in vitro* evidence that GAPDH forms a direct protein-protein interaction with the GluR2 subunit through the Y₁₄₂-K₁₇₂ region of the GluR2_{NT}.

Agonist-facilitated GluR2/GAPDH complex formation occurs extracellularly

As the NT region of GluR2 locates extracellularly, we then investigated whether the GluR2/GAPDH interaction occurs extracellularly by performing cell surface biotinylation experiments in primary culture of rat hippocampus, in which cell surface proteins of neurons were labeled with sulfo-NHS-LC-biotin. As shown in Figure 2A, the GluR2 antibody precipitated GAPDH from the biotinylated (B, cell surface) fraction, but failed to pull down GAPDH from the non-biotinylated (NB, intracellular) fraction, suggesting that the GluR2/GAPDH complex formation occurs extracellularly. Consistent with our findings, a previous study demonstrated that GAPDH was constitutively secreted into the extracellular space in several mammalian cell lines including HEK-293 T cells and neuro-2a cells [37]. We therefore speculated that GAPDH might be secreted into the extracellular space and form a protein complex with GluR2_{NT}. To test our hypothesis, we first confirmed GAPDH secretion in our cell lines by immunoprecipitating GAPDH from the conditioned medium (incubation with neurons/cells for 24 hours) of hippocampal primary cultures with a primary antibody against GAPDH. As shown in Figure 2B, GAPDH was immunoprecipitated from conditioned medium, but not from fresh medium. To further exclude the possibility that the observed



GAPDH in the conditioned medium resulted from cell lysis, conditioned media from non-transfected HEK-293 T cells and from cells expressing GluR1/2 subunits were collected, concentrated and examined by Western blot analyses using anti-GAPDH and anti- α -tubulin antibodies. As shown in Figure 2C, regardless of GluR1/2 subunit expression, GAPDH was detected from both conditioned media and cell lysates, whereas α -tubulin (a cytoplasmic protein marker) was only

detected from cell lysates, indicating that the GAPDH found in the conditioned medium is secreted from cells and is not a contaminant due to cell lysis.

Furthermore, we examined the effect of the AMPAR activation on the formation of GluR2/GAPDH complex. By conducting Co-IP experiments, we found that AMPAR activation with either 100 μ M glutamate in HEK-293 T cells expressing GluR1/2 subunits or 100 μ M kainic acid (KA) in hippocampal neurons facilitated the




Figure 2 GluR2/GAPDH interaction occurs extracellularly. **A**, Rat hippocampal neurons were incubated with sulfo-NHS-LC biotin to label cell surface proteins. GAPDH that co-immunoprecipitated with GluR2 antibody was examined in both non-biotinylated (NB) and biotinylated (B) proteins. **B**, Using a rabbit anti-GAPDH antibody, GAPDH was immunoprecipitated from the conditioned medium (CM; medium incubated with neurons/cells for 24 hours) of primary cultures of rat hippocampus but not from fresh medium. A mouse GAPDH antibody was used for Western blotting and rabbit IgG was used as negative control. **C**, Western blot analysis of GAPDH and α -tubulin in concentrated conditioned medium of non-transfected HEK-293 T cells (non-T) and HEK-293 T cells transfected with GluR1/2 subunits (AMPA), in the presence or absence of glutamate (AMPA + Glut). Cell lysates were used as controls. **D-E**: Coimmunoprecipitation of GAPDH by primary antibody against GluR2 subunit (with or without glutamate treatment) from HEK-293 T cells expressing GluR1/2 subunits (**D**) and hippocampal neurons (**E**) pre-treated with GluR2_{NT1-3-2} or GluR2_{NT1-3-2-scram} peptides (top panels). Each Coimmunoprecipitation was in parallel with Western blot analysis of the directly immunoprecipitated proteins (bottom panels). All western blot analysis and co-immunoprecipitation assays in this figure are representative of at least 3 independent experiments.

GluR2/GAPDH complex formation by $75 \pm 18\%$ and $58 \pm 11\%$ (mean \pm SEM, $n = 3$), respectively (Figure 2D, E; top panels). In each Co-IP experiment, 500 μ g of protein were incubated in the presence of primary antibodies anti-GluR2 or rabbit IgG, and 50 μ g of extracted protein was used as positive control. The level of directly immunoprecipitated GluR2 subunit was not significantly altered by the agonist stimulation (Figure 2D, E; bottom panels). If the GluR2_{NT1-3-2} region is essential for GluR2 to interact with GAPDH, application of the peptide encoding GluR2_{NT1-3-2} would disrupt the GluR2/GAPDH interaction by competing with GluR2 for GAPDH. As expected, pre-incubation of the GluR2_{NT1-3-2} peptide (10 μ M, 1 hour), but not the scrambled GluR2_{NT1-3-2} peptide (GluR2_{NT1-3-2Scram}), significantly inhibited the agonist-induced increase of the GluR2/GAPDH complex

formation in transfected HEK-293 T cells (Figure 2D, $65 \pm 8\%$ decrease; mean \pm SE, $n = 3$) and in hippocampal neurons (Figure 2E, $46 \pm 6\%$ decrease; mean \pm SE, $n = 3$). The fact that extracellular application of the interfering GluR2_{NT1-3-2} peptide was able to disrupt the GluR2/GAPDH interaction further supports the notion that the GluR2/GAPDH complex formation occurs extracellularly.

Disruption of GluR2/GAPDH interaction inhibits AMPAR-mediated excitotoxicity

Both AMPAR and GAPDH have been independently shown to be involved in cell toxicity [38-42]. The observation that AMPAR activation promoted GluR2/GAPDH complex formation suggested that the GluR2/GAPDH interaction might be involved in AMPAR-mediated excitotoxicity. Before conducting further experiments, we first confirmed the

ability of glutamate (300 μ M, 24 hour; plus 25 μ M cyclothiazide to prevent AMPAR desensitization) to induce cell death in HEK-293 T cells expressing GluR1/2 (Figure 3A), which is consistent with previous studies [43,44]. To investigate the role of the GluR2/GAPDH interaction in AMPAR-mediated cell death, HEK-293 T cells expressing GluR1/2 were pre-treated with the GluR2_{NT1-3-2} peptide (10 μ M, 1 hour), which is able to disrupt the GluR2/GAPDH association (confirmed in Figure 2D). As shown in Figure 3B, pre-incubation with the GluR2_{NT1-3-2} peptide significantly attenuated glutamate-induced (300 μ M, 500 μ M) cell death. The

GluR2_{NT1-3-2} peptide itself showed no effect in either the absence of glutamate treatment (Figure 3B) or in non-transfected cells regardless of glutamate treatment (Figure 3C). The specificity of the GluR2_{NT1-3-2} peptide was also confirmed in HEK-293 T cells expressing GluR1/3, GluR1/4 or GluR3/4 subunits, where pre-incubation with the GluR2_{NT1-3-2} peptide failed to inhibit AMPAR-mediated cell death (Figure 3D).

To study the GluR2/GAPDH interaction in a relevant cellular milieu, rat hippocampal neurons were utilized in parallel experiments. We previously confirmed in Figure 2E




Figure 3 Regulation of the AMPAR-mediated cell death in transfected cells. **A**, Bar graph summarizing the quantitative measurements of PI fluorescence from HEK-293 T cells expressing GluR1/2 subunits with/without glutamate treatment (300 μ M glutamate, 25 μ M CTZ, 24 hr). ***Significantly different from control group ($P < 0.001$, $n = 9$ per group), t-test. **B**, Bar graph summarizing the quantitative measurements of PI fluorescence from HEK-293 T cells expressing GluR1/2 subunits with/without glutamate treatment at various doses in the presence/absence of GluR2_{NT1-3-2} peptide (10 μ M, 1 hr). **, *** Significantly different from control group ($P < 0.01$, 0.001), ANOVA followed by *post-hoc* SNK test; ##, significant from the corresponding glutamate group ($P < 0.01$, $n = 9$ per group), t-test. **C**, Bar graph summarizing the quantitative measurements of PI fluorescence from non-transfected HEK-293 T cells or HEK-293 T cells expressing GluR1/2 subunits. Cells were pre-treated with the GluR2_{NT1-3-2} peptide with/without glutamate treatment ($n = 9$ per group). **D**, Bar graph summarizing the quantitative measurements of PI fluorescence from HEK-293 T cells expressing GluR1/3, GluR1/4 or GluR3/4 subunits with glutamate treatment in the presence/absence of the GluR2_{NT1-3-2} peptide ($n = 9$ per group). All PI fluorescence measurement assays were performed 3 times independently.

that pre-incubating hippocampal neurons with the GluR2_{NT1-3-2} peptide interrupted the GluR2/GAPDH interaction promoted by the AMPAR activation. Thus, we examined whether the disruption of this interaction in hippocampal neurons by applying the GluR2_{NT1-3-2} peptide would rescue neurons from AMPAR-mediated excitotoxicity. AMPAR-mediated cell death was induced by treating neurons with KA (100 μ M, 1 hour) in the presence of NMDAR and Ca²⁺ channel antagonists (10 μ M MK-801 and 2 μ M nimodipine). As shown in Figure 4A, pretreatment with the GluR2_{NT1-3-2} peptide significantly inhibited AMPAR-mediated cell death.

AMPA-mediated toxicity is often considered a contributing, if not an underlying, causative factor in ischemia, which deprives brain cells of glucose and oxygen, causing irreversible brain damage within minutes. Cells in ischemic brain tissue undergo a number of changes: they rapidly lose their energy supplies, their membranes become depolarized, calcium loads are increased, reactive oxygen types are produced and excitotoxic effects are found. These biochemical changes are followed by irreversible changes to cellular structures and cell death. The oxygen glucose deprivation (OGD) cell lesion model represents a valid simulation of the conditions in brain ischemia [45,46]. Therefore, we assessed the effectiveness of the GluR2_{NT1-3-2} peptide to rescue cells from neurotoxic stress in the OGD model to verify the implication of the GluR2/GAPDH interaction in ischemia. As shown in Figure 4B, the GluR2_{NT1-3-2} peptide pretreatment (10 μ M, 1 hour) was able to significantly attenuate OGD-induced cell death (30.4% \pm 9.5%) in the presence of 10 μ M MK-801 and 2 μ M nimodipine.

In order to further confirm the role of GAPDH in the AMPAR-mediated cell death, GAPDH siRNA was transfected into HEK-293 T cells to block the expression of GAPDH, but not the expression of GluR2 (Figure 4C). As shown in Figure 4D-E, AMPAR-mediated cell death was significantly attenuated in the presence of GAPDH siRNA. Together, these data suggest that the GluR2/GAPDH interaction may play a critical role in the GluR2-containing AMPAR-mediated cell death.

Activation of AMPAR induces AMPAR/GAPDH complex internalization through the GluR2/GAPDH interaction

Previous studies demonstrated that agonist stimulation could induce AMPAR endocytosis [47-49]. Thus, we examined whether the extracellular GAPDH would internalize along with AMPAR through the GluR2/GAPDH interaction upon the activation of AMPAR. To quantify GluR2 and GAPDH cell surface levels in HEK-293 T cells expressing GluR1/2, a cell-based ELISA assay was applied as previously described [49,50]. We first confirmed the results from previous studies that the glutamate stimulation

(100 μ M, 30 minutes) induced a significant decrease in plasma membrane GluR2 (Figure 5A). We then tested whether the cell surface-associated GAPDH is also decreased upon agonist stimulation of AMPAR. As shown in Figure 5B, activation of AMPAR significantly decreased the cell surface-associated GAPDH in HEK-293 T cells expressing GluR1/2, a phenomena that can be abolished by the pre-treatment of GluR2_{NT1-3-2} peptide. These data, together with the inability of glutamate stimulation to internalize the cell surface-associated GAPDH in the non-transfected HEK-293 T cells (Figure 5C) or HEK-293 T cells transfected with GluR1/3 subunits (Figure 5D), suggest that GAPDH internalization may be a passive process enabled by the GluR2/GAPDH interaction.

To further investigate whether the observed GAPDH internalization is dependent on the GluR2 internalization, we tested whether blockade of GluR2 endocytosis will inhibit GAPDH internalization. Previous studies demonstrated that GluR2 endocytosis is dynamin-dependent and that the expression of the dominant-negative dynamin mutant (K44E) was able to block the GluR2 internalization [47,49]. Thus, after confirming the ability of the K44E mutant to block the GluR2 internalization (Figure 5E), we examined whether the K44E mutant affected cell surface-associated GAPDH internalization in HEK-293 T cells expressing GluR1/2 subunits. As shown in Figure 5F, the K44E mutant significantly inhibited glutamate-induced cell surface-associated GAPDH internalization, indicating that GAPDH internalized through a dynamin-dependent pathway and further confirmed that GAPDH was co-internalize with the GluR2 subunit. Moreover, the K44E mutant also attenuated glutamate-induced cell death in HEK-293 T cells expressing GluR1/2 subunits (Figure 5G), indicating that GluR2/GAPDH complex internalization may play an important role in the GluR2-containing AMPAR-mediated cell death.

Discussion

AMPA-mediated excitotoxicity has been implicated in the pathogenesis of neuronal loss associated with a number of brain disorders, including transient forebrain ischemia [8-20]. However, the underlying mechanisms remain unclear. An uncontrollable rise in intracellular Ca²⁺ and Zn²⁺, with subsequent activation of diverse downstream cell death signals has been one of the most prominent hypotheses to explain excitotoxic neuronal death [19,20,51-55]. Although GluR2-containing AMPARs are calcium impermeable, recent studies have suggested that selective reductions in the expression of GluR2, resulting in an increase in Ca²⁺-permeable AMPA receptors, have been associated with an increased vulnerability of neurons to ischemic injury [16,56-61]. Although the mechanisms involved are not fully understood, it has been




Figure 4 Regulation of the AMPAR-mediated cell death in cultured neurons and OGD model. **A**, Bar graph summarizing the quantitative measurements of PI fluorescence from rat hippocampal primary culture with KA treatment (100 μ M, 1 hr) in the presence/absence of the GluR2_{NT1-3-2} peptide. ***Significantly different from KA group ($P < 0.001$, $n = 9$ per group), t-test. **B**, Bar graph summarizing the quantitative measurements of PI fluorescence from rat hippocampal primary culture with OGD protocol in the presence/absence of the GluR2_{NT1-3-2} peptide. *Significantly different from OGD group ($P < 0.05$, $n = 9$ per group), t-test. **C**, Western blot analysis of GAPDH (upper panel) and GluR2 (lower panel) expression in HEK 293 T cells expressing GluR1/2 subunits in the presence/absence of the GAPDH siRNA. **D**, Bar graph summarizing the quantitative measurements of PI fluorescence from HEK-293 T cells expressing GluR1/2 subunits with glutamate treatment in the presence/absence of the GAPDH siRNA ($P < 0.05$, $n = 9$ per group), t-test. **E**, Propidium iodide positive cells (red) from HEK-293 T expressing GluR1/2 subunits with glutamate treatment in the presence/absence of the GAPDH siRNA, scale bar 50 μ m. All PI fluorescence measurement assays were performed 3 times independently.

suggested that GluR2 internalization may enhance the Ca^{2+} -influx that results in neurotoxicity, either through newly synthesized Ca^{2+} -permeable AMPARs [57] or by activation of a caspase-dependent apoptotic pathway [62]. Consistent with previous studies, our data has shown that agonist stimulation of AMPAR results in the internalization of GluR2 and promotes extracellular GAPDH internalization via a GluR2/GAPDH coupling-dependent process. This is the first evidence showing that the N-terminal of the GluR2 subunit plays an important role in AMPA receptor-mediated excitotoxicity through regulating AMPAR trafficking. Many studies have shown that agonist-

induced GluR2 internalization is a dynamin-dependent process [47,49]. The observations of our study that mutant dynamin abolishes both GluR2 and GAPDH internalization and the inability of GAPDH to internalize in cells lacking GluR2 suggest that GAPDH internalization is a passive process facilitated by the GluR2/GAPDH interaction and mediated by GluR2 internalization.

Given the fact that GAPDH interacts with the extracellular NT of GluR2, it is likely that the GluR2/GAPDH protein complex may be in an endocytosed vesicle following the agonist-induced internalization. On this basis it would be logical to further ask how the GluR2/GAPDH complex gets




Figure 5 Activation of AMPAR induces GluR2/GAPDH co-internalization. **A**, Quantification of GluR2 expression at the plasma membrane with/without glutamate treatment (100 μ M, 30 minutes) in HEK-293 T cells expressing GluR1/2 subunits. *Significantly different from control group ($P < 0.05$, $n = 9$ per group), t-test. **B**, Quantification of cell surface-associated GAPDH with/without glutamate treatment in the presence/absence of the GluR2_{NT1-3-2} peptide in HEK-293 T cells expressing GluR1/2 subunits. *Significantly different from control group; #, significantly different from glutamate group ($P < 0.05$, $n = 9$ per group), ANOVA followed by *post-hoc* SNK test. **C**, Quantification of cell surface-associated GAPDH in non-transfected HEK-293 T cells with/without glutamate treatment ($n = 9$ per group). **D**, Quantification of cell surface-associated GAPDH with/without glutamate treatment in HEK-293 T cells expressing GluR1/3 subunits ($n = 9$ per group). Quantification of plasma membrane GluR2 (**E**) or cell surface-associated GAPDH (**F**) expression at the plasma membrane with/without glutamate treatment in HEK-293 T cells expressing GluR1/2 subunits with wild type dynamin (WT) or mutant K44E dynamin (K44E). *Significantly different from the corresponding control group ($P < 0.05$, $n = 9$ per group), t-test. **G**, Bar graph summarizing the quantitative measurements of PI fluorescence from HEK-293 T cells expressing GluR1/2 subunits with wild type dynamin (WT) or mutant K44E dynamin (K44E) with/without glutamate treatment. ***Significantly different from control WT group ($P < 0.001$, $n = 9$ per group); ##significantly different from control K44E group ($P < 0.01$, $n = 9$ per group), t-test. All assays in this figure were performed 3 times independently.

out of the vesicle and promotes excitotoxic neuronal death. There are many possibilities for this question. First, the complex may be transported to the nucleus via a retrograde vesicle transport mechanism leading to the fusion of the

vesicle with ER or nuclear membranes or via mechanisms recently proposed for the nuclear translocation of another plasma membrane receptor, the EGF receptor [63,64]. Second, the GluR2/GAPDH complex formation in the

vesicle may lead to the activation of lysosome in the vesicle that breaks the vesicle and release the GluR2/GAPDH into the cytoplasm.

The possible mechanisms that underlie this GluR2/GAPDH related cell death is particularly interesting. It is somewhat surprising to find that the AMPAR-mediated cell death involves GAPDH, a key enzyme involved in glycolysis with a ubiquitous intracellular distribution. However, additional roles for GAPDH have been discovered recently, including membrane fusion/transport, binding to low molecular weight G proteins, regulation of the cytoskeleton, accumulation of glutamate into presynaptic vesicles, and apoptosis [65-71]. Recent studies have shown that GAPDH binds to Siah1 and triggers apoptosis [39]. Moreover GAPDH has also been reported to interact with p53 [72], a tumor suppressor and transcription factor that has been implicated in glutamate-mediated excitotoxicity [73-75]. Numerous evidence show that activation of p53 can trigger apoptosis (for reviews, see [76]) under conditions of cellular stress mediated by phosphorylation or acetylation of p53 [77]. Whether Siah1, p53 or other molecules are involved in GluR2/GAPDH-related cell death pathway requires much more additional work for a better understanding of the detailed molecular mechanisms.

Stroke is the second leading cause of death worldwide yet there are very few effective pharmacological treatments for patients suffering ischemic stroke. Thrombolytics such as alteplase and tenecteplase have been a significant advance in the treatment of ischemic stroke. However, thrombolytics must be given soon after a stroke to be effective (within 3 hours of ischemic episode). This short time frame has limited their use in many situations. There continues to be a significant unmet need for acute pharmacological treatments beyond thrombolytics. Advances in recent years include hypothermia [78-80], oxygen therapy [81], stem cell transplantation [82] and cerebral plasticity stimulation (trophic factor) strategies [83]. These novel techniques are intriguing, but will require further well-designed prospective trials to assess clinical feasibility, safety, and efficacy [84]. Another approach that has received considerable attention is agents that inhibit ischemia-induced excitotoxicity though directly blocking glutamate receptors. However, all have failed at various stages of development for a variety of reasons. One of the main drawbacks of the glutamate receptor antagonists is that they block normal excitatory neurotransmission necessary for maintaining basic brain functions. For this reason, much research has been directed at identifying drugs and peptides that may be able to selectively target protein-protein interactions that have more narrow function than a certain neurotransmitter receptor. In the present study, we have shown that administration of the interfering GluR2_{NT1-3-2} peptide to interrupt

the GluR2/GAPDH interaction significantly mitigates neuronal cell death in a cell model of ischemia, revealing a previously unappreciated signaling pathway underlying AMPAR-mediated excitotoxicity and it may provide a new avenue for the development of a complementary therapeutics in the treatment of neuropathological disorders, such as stroke and epilepsy.

Materials and methods

Cell culture and transient transfection

HEK293 T cells were cultured in α -MEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen) and maintained in incubators at 37°C, 5% CO₂. HEK293T cells were transiently transfected with plasmid constructs and/or siRNA using lipofectamine 2000 reagents (Invitrogen). Cells were harvested 48 hours post transfection.

Primary hippocampal neuron culture and OGD treatment

Primary cultures from hippocampus were prepared from fetal Wistar rats (embryonic day 17–19) on Cell + (Sarstedt) culture dishes as previously described [85-87]. The cultures were used for experiments on 12–15 days after plating. Hippocampal cultures were pretreated GluR2_{NT1-3-2} peptides prior to kainic acid treatment. OGD treatment was performed in the presence of MK-801 and nimodipine as previously described [57].

GST fusion proteins

To construct GST-fusion proteins encoding truncated GluR2 and GAPDH, cDNA fragments were amplified by using PCR method with specific primers. Except where specified, all 5' and 3' oligonucleotides incorporated BamH1 site (GGATCC) and Xho1 sites (CTCGAG), respectively, to facilitate subcloning into vector pGEX-4T3 (for GST-fusion protein construction). GST-fusion proteins were prepared from bacterial lysates with Glutathione Sepharose 4B beads as described by the manufacturer (Amersham). To confirm appropriate splice fusion and the absence of spurious PCR generated nucleotide errors, all constructs were resequenced.

Protein affinity purification, *in vitro* binding, co-immunoprecipitation and western blot

Protein affinity purification, *in vitro* binding, co-immunoprecipitation and Western blot analyses were performed as previously described [85-87]. Antibodies used for immunoprecipitation, Western blots and cell surface ELISA assays include GAPDH (polyclonal from Abcam, monoclonal from Chemicon), GluR2 (Western blots: Chemicon; immunoprecipitation: Upstate), and α -tubulin (monoclonal, Sigma-Aldrich).

Cell-ELISA assays

HEK-293 T cells transfected with plasmid constructs were treated with 100 μ M glutamate or extracellular solution (ECS) before fixing in 4% (W/V) paraformaldehyde for 10 minutes in the absence (non-permeabilized conditions) or presence (permeabilized conditions) of 1% (V/V) Triton X-100. Cells were incubated in 1% (W/V) glycine for 10 minutes at 4°C to recover from the fixing. Cells were then incubated with specific primary antibodies for the purpose of labeling the receptors or proteins on the cell surface under non-permeabilized conditions or the entire receptor pool under permeabilized conditions. After incubation with corresponding HRP-conjugated secondary antibodies (Sigma-Aldrich), the HRP substrate o-phenylenediamine (Sigma-Aldrich) was added to produce a color reaction that was stopped with the equal volume of 3 N HCl. Fluorescence intensity in each well was measured with a plate reader (Victor3; PerkinElmer). The cell surface expression of HA-GluR2 after pre-treatment with glutamate was presented as the ratio of colorimetric readings under non-permeabilized conditions to those under permeabilized conditions, and then normalized to their respective control groups (pretreated with ECS). Afterwards, cells were scrapped from the dishes, and the protein concentration of each dish was measured. The results of cell surface expression of receptors or proteins were calibrated by the protein concentration of each well. Analysis was done using at least 9 separate wells in each group. Cell ELISA using primary hippocampal neurons was performed identically with assays using HEK-293 T cells, with the exception that the anti-GluR2 antibody (MAB397; Chemicon) was used as primary antibody instead of anti-HA.

Quantification of AMPAR-mediated excitotoxicity

HEK-293 T cells transfected with GluR1/2 subunits were exposed to 300 μ M glutamate/25 μ M cyclothiazide at 37°C for 24 hours. Cells were allowed to recover for 24 hours at 37°C. To quantify AMPAR-mediated cell death, culture medium was replaced by extracellular solution containing 50 μ g/ml of propidium iodide (PI) (Invitrogen, Carlsbad, CA). After 30 minutes incubation at 37°C, fluorescence intensity in each well was measured with a plate reader (Victor3; PerkinElmer, Waltham, MA). The fraction of dead cells was normalized to the total cell number. Primary hippocampal neurons were exposed to 100 μ M KA/25 μ M cyclothiazide in the presence of NMDAR and Ca²⁺ channel antagonists (10 μ M MK-801 and 2 μ M nimodipine, respectively) at 37°C for 1 hour.

Cell biotinylation

For cell surface biotinylation, cells were rinsed four times with ice-cold PBS²⁺ (PBS containing 0.1 mM CaCl₂ and 1.0 mM MgCl₂) after treatment, and incubated twice

with 1.0 mg/ml sulfo-NHS-LC-biotin (Pierce, Rockford, IL) for 20 minutes at 4°C. Non-reactive biotin was quenched by 20 minutes incubation at 4°C in ice-cold PBS²⁺ and 0.1 M glycine. Cells were solubilized in RIPA buffer (10 mM Tris, pH7.4, 150 mM NaCl, 1.0 mM EDTA, 0.1% (W/V) SDS, 1.0% (V/V) Triton X-100 and 1.0% (V/V) Sodium deoxycholate) containing protease inhibitors (1.0 mM PMSF and 1.0 μ g/ml protease cocktail). Biotinylated and non-biotinylated proteins were separated from equal amounts of cellular protein by incubation with 50 μ l of 50% slurry of immobilized streptavidin-conjugated beads (Pierce, Rockford, IL) overnight with constant mixing at 4°C. Unbound proteins (supernatant) were saved for later co-immunoprecipitation experiment. Proteins bound to streptavidin beads were eluted in biotin elution buffer. Biotinylated and non-biotinylated samples were applied to protein A/G PLUS-agarose (Santa Cruz Biotechnology, Santa Cruz, CA) for co-immunoprecipitation.

Competing Interest

The authors declare that they have no competing interests.

Acknowledgments

We gratefully acknowledge Mr. Brian Vukusic for technical assistance. We thank Dr. Paul Talyor for help with the MS experiments and analysis. We thank Dr. Qi Wan for providing the OGD cell model. F.L. is a recipient of Career Investigator Award of the Heart and Stroke Foundation of Canada. S.P. L. is a recipient of post-doctoral fellowship of the Heart and Stroke Foundation of Canada. The work is supported by operating grant from Heart and Stroke Foundation of Canada (F. L.).

Author details

¹Department of Neuroscience, Centre for Addiction and Mental Health, Toronto, Canada. ²Brain Research Center, University of British Columbia, Vancouver, Canada. ³Department of Psychiatry, University of Toronto, Toronto, Canada. ⁴Department of Neuroscience, Centre for Addiction and Mental Health, Clarke Division, 250 College Street, Toronto, ON M5T 1R8, Canada.

Authors' contributions

MW carried out all experiments, with the help of SL for constructing GST-fusion proteins, HZ for AMPAR-mediated excitotoxicity assays, LP for the co-immunoprecipitation and SZ for the GST-pull down assays. FJK and YTW helped to edit the manuscript. FL supervised the study and wrote the manuscript. All authors read and approved the final manuscript.

Received: 10 March 2012 Accepted: 26 April 2012

Published: 26 April 2012

References

1. Bliss TV, Collingridge GL: A synaptic model of memory: long-term potentiation in the hippocampus. *Nature* 1993, **361**:31–39.
2. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. *Neuron* 1988, **1**:623–634.
3. Hollmann M, Heinemann S: Cloned glutamate receptors. *Annu Rev Neurosci* 1994, **17**:31–108.
4. Keinänen K, Wisden W, Sommer B, Werner P, Herb A, Verdoorn TA, Sakmann B, Seeburg PH: A family of AMPA-selective glutamate receptors. *Science* 1990, **249**:556–560.
5. Boulter J, Hollmann M, O'Shea-Greenfield A, Hartley M, Deneris E, Maron C, Heinemann S: Molecular cloning and functional expression of glutamate receptor subunit genes. *Science* 1990, **249**:1033–1037.
6. Choi DW: Calcium: still center-stage in hypoxic-ischemic neuronal death. *Trends Neurosci* 1995, **18**:58–60.

7. Simon RP, Swan JH, Griffiths T, Meldrum BS: **Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain.** *Science* 1984, **226**:850–852.
8. Dos-Anjos S, Martinez-Villayandre B, Montori S, Regueiro-Purrinos MM, Gonzalo-Orden JM, Fernandez-Lopez A: **Global ischemia-induced modifications in the expression of AMPA receptors and inflammation in rat brain.** *Brain Res* 2009, **1287**:20–27.
9. Elger B, Gieseler M, Schmucker O, Schumann I, Seltz A, Huth A: **Extended therapeutic time window after focal cerebral ischemia by non-competitive inhibition of AMPA receptors.** *Brain Res* 2006, **1085**:189–194.
10. Gill R, Lodge D: **Pharmacology of AMPA antagonists and their role in neuroprotection.** *Int Rev Neurobiol* 1997, **40**:197–232.
11. Gressens P, Spedding M, Gigler G, Kertesz S, Villa P, Medja F, Williamson T, Kapus G, Levay G, Szenasi G, et al: **The effects of AMPA receptor antagonists in models of stroke and neurodegeneration.** *Eur J Pharmacol* 2005, **519**:58–67.
12. Matusz E, Moricz K, Gigler G, Simo A, Barkoczy J, Levay G, Harsing LG Jr, Szenasi G: **Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia.** *Brain Res* 2004, **1019**:210–216.
13. McCarran WJ, Goldberg MP: **White matter axon vulnerability to AMPA/kainate receptor-mediated ischemic injury is developmentally regulated.** *J Neurosci* 2007, **27**:4220–4229.
14. Oguro K, Oguro N, Kojima T, Grooms SY, Calderone A, Zheng X, Bennett MV, Zukin RS: **Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons.** *J Neurosci* 1999, **19**:9218–9227.
15. Pellegrini-Giampietro DE, Zukin RS, Bennett MV, Cho S, Pulsinelli WA: **Switch in glutamate receptor subunit gene expression in CA1 subfield of hippocampus following global ischemia in rats.** *Proc Natl Acad Sci USA* 1992, **89**:10499–10503.
16. Peng PL, Zhong X, Tu W, Soundarapandian MM, Molner P, Zhu D, Lau L, Liu S, Liu F, Lu Y: **ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia.** *Neuron* 2006, **49**:719–733.
17. Pulsinelli WA, Levy DE, Duffy TE: **Regional cerebral blood flow and glucose metabolism following transient forebrain ischemia.** *Ann Neurol* 1982, **11**:499–502.
18. Schmidt-Kastner R, Freund TF: **Selective vulnerability of the hippocampus in brain ischemia.** *Neuroscience* 1991, **40**:599–636.
19. Weiss JH, Sensi SL: **Ca²⁺-Zn²⁺ permeable AMPA or kainate receptors: possible key factors in selective neurodegeneration.** *Trends Neurosci* 2000, **23**:365–371.
20. Yin HZ, Sensi SL, Ogoshi F, Weiss JH: **Blockade of Ca²⁺-permeable AMPA/kainate channels decreases oxygen-glucose deprivation-induced Zn²⁺ accumulation and neuronal loss in hippocampal pyramidal neurons.** *J Neurosci* 2002, **22**:1273–1279.
21. Tanaka H, Grooms SY, Bennett MV, Zukin RS: **The AMPAR subunit GluR2: still front and center-stage.** *Brain Res* 2000, **886**:190–207.
22. Geiger JR, Melcher T, Koh DS, Sakmann B, Seeburg PH, Jonas P, Monyer H: **Relative abundance of subunit mRNAs determines gating and Ca²⁺ permeability of AMPA receptors in principal neurons and interneurons in rat CNS.** *Neuron* 1995, **15**:193–204.
23. Greger IH, Khatri L, Ziff EB: **RNA editing at arg607 controls AMPA receptor exit from the endoplasmic reticulum.** *Neuron* 2002, **34**:759–772.
24. Jonas P, Racca C, Sakmann B, Seeburg PH, Monyer H: **Differences in Ca²⁺ permeability of AMPA-type glutamate receptor channels in neocortical neurons caused by differential GluR-B subunit expression.** *Neuron* 1994, **12**:1281–1289.
25. Lu W, Shi Y, Jackson AC, Bjorgan K, Daring MJ, Sprengel R, Seeburg PH, Nicoll RA: **Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach.** *Neuron* 2009, **62**:254–268.
26. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS: **Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons.** *J Neurosci* 1996, **16**:1982–1989.
27. Dong H, O'Brien RJ, Fung ET, Lanahan AA, Worley PF, Huganir RL: **GRIP: a synaptic PDZ domain-containing protein that interacts with AMPA receptors.** *Nature* 1997, **386**:279–284.
28. Dong H, Zhang P, Song I, Petralia RS, Liao D, Huganir RL: **Characterization of the glutamate receptor-interacting proteins GRIP1 and GRIP2.** *J Neurosci* 1999, **19**:6930–6941.
29. Lee SH, Liu L, Wang YT, Sheng M: **Clathrin adaptor AP2 and NSF interact with overlapping sites of GluR2 and play distinct roles in AMPA receptor trafficking and hippocampal LTD.** *Neuron* 2002, **36**:661–674.
30. Nishimune A, Isaac JT, Molnar E, Noel J, Nash SR, Tagaya M, Collingridge GL, Nakanishi S, Henley JM: **NSF binding to GluR2 regulates synaptic transmission.** *Neuron* 1998, **21**:87–97.
31. Osten P, Srivastava S, Inman GJ, Vilim FS, Khatri L, Lee LM, States BA, Einheber S, Milner TA, Hanson PI, Ziff EB: **The AMPA receptor GluR2 C terminus can mediate a reversible, ATP-dependent interaction with NSF and alpha- and beta-SNAPs.** *Neuron* 1998, **21**:99–110.
32. Srivastava S, Osten P, Vilim FS, Khatri L, Inman G, States B, Daly C, DeSouza S, Abagyan R, Valtschanoff JG, et al: **Novel anchorage of GluR2/3 to the postsynaptic density by the AMPA receptor-binding protein ABP.** *Neuron* 1998, **21**:581–591.
33. Wyszynski M, Valtschanoff JG, Naisbitt S, Dunah AW, Kim E, Standaert DG, Weinberg R, Sheng M: **Association of AMPA receptors with a subset of glutamate receptor-interacting protein in vivo.** *J Neurosci* 1999, **19**:6528–6537.
34. Xia J, Zhang X, Staudinger J, Huganir RL: **Clustering of AMPA receptors by the synaptic PDZ domain-containing protein PICK1.** *Neuron* 1999, **22**:179–187.
35. O'Brien RJ, Xu D, Petralia RS, Steward O, Huganir RL, Worley P: **Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp.** *Neuron* 1999, **23**:309–323.
36. Saggiotti L, Dequidt C, Kamieniarz K, Rousset MC, Valnegri P, Thoumine O, Beretta F, Fagni L, Choquet D, Sala C, et al: **Extracellular interactions between GluR2 and N-cadherin in spine regulation.** *Neuron* 2007, **54**:461–477.
37. Yamaji R, Chatani E, Harada N, Sugimoto K, Inui H, Nakano Y: **Glyceraldehyde-3-phosphate dehydrogenase in the extracellular space inhibits cell spreading.** *Biochim Biophys Acta* 2005, **1726**:261–271.
38. Chuang DM, Hough C, Senatorov VV: **Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases.** *Annu Rev Pharmacol Toxicol* 2005, **45**:269–290.
39. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, Ozeki Y, Takahashi M, Cheah JH, Tankou SK, Hester LD, et al: **S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding.** *Nat Cell Biol* 2005, **7**:665–674.
40. Ishitani R, Chuang DM: **Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons.** *Proc Natl Acad Sci USA* 1996, **93**:9937–9941.
41. Ishitani R, Tanaka M, Sunaga K, Katsube N, Chuang DM: **Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis.** *Mol Pharmacol* 1998, **53**:701–707.
42. Sawa A, Khan AA, Hester LD, Snyder SH: **Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death.** *Proc Natl Acad Sci USA* 1997, **94**:11669–11674.
43. Iihara K, Joo DT, Henderson J, Sattler R, Taverna FA, Lourensen S, Orser BA, Roder JC, Tymianski M: **The influence of glutamate receptor 2 expression on excitotoxicity in GluR2 null mutant mice.** *J Neurosci* 2001, **21**:2224–2239.
44. Zeevalk GD, Schoepp D, Nicklas WJ: **Excitotoxicity at both NMDA and non-NMDA glutamate receptors is antagonized by aurointricarboxylic acid: evidence for differing mechanisms of action.** *J Neurochem* 1995, **64**:1749–1758.
45. Goldberg MP, Choi DW: **Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury.** *J Neurosci* 1993, **13**:3510–3524.
46. Ying HS, Weishaupt JH, Grabb M, Canzoniero LM, Sensi SL, Sheline CT, Monyer H, Choi DW: **Sublethal oxygen-glucose deprivation alters hippocampal neuronal AMPA receptor expression and vulnerability to kainate-induced death.** *J Neurosci* 1997, **17**:9536–9544.
47. Carroll RC, Beattie EC, Xia H, Luscher C, Altschuler Y, Nicoll RA, Malenka RC, von Zastrow M: **Dynamin-dependent endocytosis of ionotropic glutamate receptors.** *Proc Natl Acad Sci USA* 1999, **96**:14112–14117.
48. Lin JW, Ju W, Foster K, Lee SH, Ahmadian G, Wyszynski M, Wang YT, Sheng M: **Distinct molecular mechanisms and divergent endocytotic pathways of AMPA receptor internalization.** *Nat Neurosci* 2000, **3**:1282–1290.
49. Man HY, Lin JW, Ju WH, Ahmadian G, Liu L, Becker LE, Sheng M, Wang YT: **Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization.** *Neuron* 2000, **25**:649–662.
50. Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F: **Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors.** *J Neurosci* 2004, **24**:1149–1158.

51. Sensi SL, Yin HZ, Carriedo SG, Rao SS, Weiss JH: Preferential Zn²⁺ influx through Ca²⁺-permeable AMPA/kainate channels triggers prolonged mitochondrial superoxide production. *Proc Natl Acad Sci USA* 1999, **96**:2414–2419.
52. Sensi SL, Ton-That D, Sullivan PG, Jonas EA, Gee KR, Kaczmarek LK, Weiss JH: Modulation of mitochondrial function by endogenous Zn²⁺ pools. *Proc Natl Acad Sci USA* 2003, **100**:6157–6162.
53. Medvedeva YV, Lin B, Shuttleworth CW, Weiss JH: Intracellular Zn²⁺ accumulation contributes to synaptic failure, mitochondrial depolarization, and cell death in an acute slice oxygen-glucose deprivation model of ischemia. *J Neurosci* 2009, **29**:1105–1114.
54. Jiang D, Sullivan PG, Sensi SL, Steward O, Weiss JH: Zn(2+) induces permeability transition pore opening and release of pro-apoptotic peptides from neuronal mitochondria. *J Biol Chem* 2001, **276**:47524–47529.
55. Bossy-Wetzel E, Talantova MV, Lee WD, Scholzke MN, Harrop A, Mathews E, Gotz T, Han J, Ellisman MH, Perkins GA, Lipton SA: Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K⁺ channels. *Neuron* 2004, **41**:351–365.
56. Kwak S, Weiss JH: Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. *Curr Opin Neurobiol* 2006, **16**:281–287.
57. Liu B, Liao M, Mielke JG, Ning K, Chen Y, Li L, El-Hayek YH, Gomez E, Zukin RS, Fehlings MG, Wan Q: Ischemic insults direct glutamate receptor subunit 2-lacking AMPA receptors to synaptic sites. *J Neurosci* 2006, **26**:5309–5319.
58. Soundarapandian MM, Tu WH, Peng PL, Zervos AS, Lu Y: AMPA receptor subunit GluR2 gates injurious signals in ischemic stroke. *Mol Neurobiol* 2005, **32**:145–155.
59. Spaethling JM, Klein DM, Singh P, Meaney DF: Calcium-permeable AMPA receptors appear in cortical neurons after traumatic mechanical injury and contribute to neuronal fate. *J Neurotrauma* 2008, **25**:1207–1216.
60. Anzai T, Tsuzuki K, Yamada N, Hayashi T, Iwakuma M, Inada K, Kameyama K, Hoka S, Saji M: Overexpression of Ca²⁺-permeable AMPA receptor promotes delayed cell death of hippocampal CA1 neurons following transient forebrain ischemia. *Neurosci Res* 2003, **46**:41–51.
61. Liu S, Lau L, Wei J, Zhu D, Zou S, Sun HS, Fu Y, Liu F, Lu Y: Expression of Ca (2+)-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. *Neuron* 2004, **43**:43–55.
62. Li SY, Ni JH, Xu DS, Jia HT: Down-regulation of GluR2 is associated with Ca²⁺-dependent protease activities in kainate-induced apoptotic cell death in cultured [correction of cultured] rat hippocampal neurons. *Neurosci Lett* 2003, **352**:105–108.
63. Dittmann K, Mayer C, Kehlbach R, Rodemann HP: Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. *Mol Cancer* 2008, **7**:69.
64. Liao HJ, Carpenter G: Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. *Mol Biol Cell* 2007, **18**:1064–1072.
65. Doucet JP, Tuana BS: Identification of low molecular weight GTP-binding proteins and their sites of interaction in subcellular fractions from skeletal muscle. *J Biol Chem* 1991, **266**:17613–17620.
66. Fuchtbauer A, Jockusch BM, Leberer E, Pette D: Actin-severing activity copurifies with phosphofructokinase. *Proc Natl Acad Sci USA* 1986, **83**:9502–9506.
67. Glaser PE, Gross RW: Rapid plasmenylethanolamine-selective fusion of membrane bilayers catalyzed by an isoform of glyceraldehyde-3-phosphate dehydrogenase: discrimination between glycolytic and fusogenic roles of individual isoforms. *Biochemistry* 1995, **34**:12193–12203.
68. Huitorel P, Pantaloni D: Bundling of microtubules by glyceraldehyde-3-phosphate dehydrogenase and its modulation by ATP. *Eur J Biochem* 1985, **150**:265–269.
69. Ikemoto A, Bole DG, Ueda T: Glycolysis and glutamate accumulation into synaptic vesicles. Role of glyceraldehyde phosphate dehydrogenase and 3-phosphoglycerate kinase. *J Biol Chem* 2003, **278**:5929–5940.
70. Robbins AR, Ward RD, Oliver C: A mutation in glyceraldehyde 3-phosphate dehydrogenase alters endocytosis in CHO cells. *J Cell Biol* 1995, **130**:1093–1104.
71. Tisdale EJ: Glyceraldehyde-3-phosphate dehydrogenase is required for vesicular transport in the early secretory pathway. *J Biol Chem* 2001, **276**:2480–2486.
72. Chen RW, Saunders PA, Wei H, Li Z, Seth P, Chuang DM: Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. *J Neurosci* 1999, **19**:9654–9662.
73. Lakkaraju A, Dubinsky JM, Low WC, Rahman YE: Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes. *J Biol Chem* 2001, **276**:32000–32007.
74. Sakhi S, Bruce A, Sun N, Tocco G, Baudry M, Schreiber SS: p53 induction is associated with neuronal damage in the central nervous system. *Proc Natl Acad Sci USA* 1994, **91**:7525–7529.
75. Uberti D, Belloni M, Grilli M, Spano P, Memo M: Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids. *Eur J Neurosci* 1998, **10**:246–254.
76. Miller FD, Pozniak CD, Walsh GS: Neuronal life and death: an essential role for the p53 family. *Cell Death Differ* 2000, **7**:880–888.
77. Brooks CL, Gu W: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. *Curr Opin Cell Biol* 2003, **15**:164–171.
78. Colbourne F, Grooms SY, Zukin RS, Buchan AM, Bennett MV: Hypothermia rescues hippocampal CA1 neurons and attenuates down-regulation of the AMPA receptor GluR2 subunit after forebrain ischemia. *Proc Natl Acad Sci USA* 2003, **100**:2906–2910.
79. Hemmen TM, Lyden PD: Induced hypothermia for acute stroke. *Stroke* 2007, **38**:794–799.
80. Linares G, Mayer SA: Hypothermia for the treatment of ischemic and hemorrhagic stroke. *Crit Care Med* 2009, **37**:S243–S249.
81. Poli S, Veltkamp R: Oxygen therapy in acute ischemic stroke - experimental efficacy and molecular mechanisms. *Curr Mol Med* 2009, **9**:227–241.
82. Burns TC, Verfaillie CM, Low WC: Stem cells for ischemic brain injury: a critical review. *J Comp Neurol* 2009, **515**:125–144.
83. Ohab JJ, Fleming S, Blesch A, Carmichael ST: A neurovascular niche for neurogenesis after stroke. *J Neurosci* 2006, **26**:13007–13016.
84. Gutierrez M, Merino JJ, de Lecinana MA, Diez-Tejedor E: Cerebral protection, brain repair, plasticity and cell therapy in ischemic stroke. *Cerebrovasc Dis* 2009, **27**(Suppl 1):177–186.
85. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F: Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. *Cell* 2002, **111**:219–230.
86. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB: Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. *Nature* 2000, **403**:274–280.
87. Zou S, Li L, Pei L, Vukusic B, Van Tol HH, Lee FJ, Wan Q, Liu F: Protein-protein coupling/uncoupling enables dopamine D2 receptor regulation of AMPA receptor-mediated excitotoxicity. *J Neurosci* 2005, **25**:4385–4395.
88. Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A, Snyder SH: Neuroprotection by pharmacologic blockade of the GAPDH death cascade. *Proc Natl Acad Sci USA* 2006, **103**:3887–3889.

doi:10.1186/1756-6606-5-13

Cite this article as: Wang et al.: Direct interaction between GluR2 and GAPDH regulates AMPAR-mediated excitotoxicity. *Molecular Brain* 2012 5:13.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

